|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
The correlation analysis revealed that advanced stage tumors (stage III-IV) had higher FAM83A expression than early stage tumors (stage I-II) (P= 0.004).
|
31594212 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Lastly, Cox multivariate survival analysis showed that FAM83A differential expression level (low vs. high) was the only independent factor predicting the prognosis of LUAD patients (P=0.001).
|
31175804 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry analysis on 86 paraffin samples further demonstrated that the LUAD tissue had higher FAM83A expression than adjacent lung tissue (P< 0.001).
|
31594212 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.040 |
Biomarker
|
disease |
BEFREE |
Of note, FAM83A has potential significance in drug resistance, and may present a candidate biomarker for the prognosis and treatment of patients with LUAD.
|
31065463 |
2019 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Here, we find that FAM83A expression is elevated in 36% of HER2+ BC tumors.
|
28463969 |
2017 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
We assessed transcriptional expression patterns of eight FAM83 family genes (FAM83A-H) across tumor types, the relationship between their expression and changes in DNA copy number, and the association with patient survival.
|
28078827 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer.
|
16354590 |
2005 |
|
Adenocarcinoma of lung (disorder)
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
BJ-TSA-9 mRNA was expressed in 52.5% (21 of 40) of human lung cancer tissues and was especially higher in lung adenocarcinoma (68.8%).
|
16354590 |
2005 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Family with sequence similarity 83, member A (FAM83A), as a potential tumor promoter, was reported to contribute to the progression of several malignant tumors.
|
31444970 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC.
|
31083571 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our findings are the first time to demonstrate that increased expression of FAM83A in NSCLC was correlated with EMT and tumor metastasis, which may provide a novel therapeutic target in NSCLC treatment.
|
31444970 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
One NAT, family with sequence similarity 83 member A antisense RNA 1 (FAM83A-AS1), was found to be markedly upregulated and positively correlated with its cognate sense counterpart, FAM83A, in NSCLC.
|
30659636 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Importantly, the FAM83A locus was amplified in a number of human cancers and silencing FAM83A in associated cancer cell lines inhibited activation of the WNT/β-catenin and TGF-β signaling pathways and reduced tumorigenicity.
|
28287611 |
2017 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Using a screen to measure reversion of malignant cells into phenotypically nonmalignant cells in 3D gels, we identified FAM83A as a candidate cancer-associated gene capable of conferring resistance to EGFR-TKIs.
|
22886303 |
2012 |
|
Adenocarcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas.
|
31527715 |
2019 |
|
Malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Family with sequence similarity 83 member A (FAM83A) can promote tumor cell proliferation and facilitate epidermal growth factor tyrosine kinase inhibitor resistance in some malignant tumors, but its role in lung cancer has not been directly explored.
|
31594212 |
2019 |
|
Malignant neoplasm of pancreas
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this study we show that FAM83A expression is significantly elevated in human and murine pancreatic cancers and is essential for the growth and tumorigenesis of pancreatic cancer cells.
|
31527715 |
2019 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
In this study we show that FAM83A expression is significantly elevated in human and murine pancreatic cancers and is essential for the growth and tumorigenesis of pancreatic cancer cells.
|
31527715 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
LY6K (lymphocyte antigen 6 complex locus K), FAM83A (family member with sequence similarity 83), CELSR3, ASF1B, IQGAP3, SEMA3F, CLDN10, MSX1, CXCL5, ASRGL1, ELAVL2, GRB7, KHSRP, NOVA1, PTBP1, and RNASEH2A were identified as novel candidate genes associated with cervical lesion progression and carcinogenesis.
|
30696738 |
2019 |
|
Carcinoma of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Family with sequence similarity 83 member A (FAM83A) can promote tumor cell proliferation and facilitate epidermal growth factor tyrosine kinase inhibitor resistance in some malignant tumors, but its role in lung cancer has not been directly explored.
|
31594212 |
2019 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Mechanically, we found that FAM83A promoted NSCLC cell migration and invasion by inducing epithelial-mesenchymal transition (EMT) via PI3K/ATK/Snail signaling.
|
31444970 |
2019 |
|
Primary malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Family with sequence similarity 83 member A (FAM83A) can promote tumor cell proliferation and facilitate epidermal growth factor tyrosine kinase inhibitor resistance in some malignant tumors, but its role in lung cancer has not been directly explored.
|
31594212 |
2019 |
|
Malignant neoplasm of pancreas
|
0.020 |
Biomarker
|
disease |
BEFREE |
Overexpression of FAM83A markedly promoted, whereas inhibition of FAM83A decreased, CSC-like traits and chemoresistance both in vitro and in an in vivo mouse model of pancreatic cancer.
|
28287611 |
2017 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Importantly, the FAM83A locus was amplified in a number of human cancers and silencing FAM83A in associated cancer cell lines inhibited activation of the WNT/β-catenin and TGF-β signaling pathways and reduced tumorigenicity.
|
28287611 |
2017 |
|
Adenocarcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
The 20 genes such as SPP1, SPINK1, and FAM83A with largest fold changes in smokers also showed similar large and highly significant fold changes in nonsmokers and vice versa, showing commonalities in expression changes for adenocarcinomas in both smokers and nonsmokers for these genes.
|
26081616 |
2015 |